Hikma Pharmaceuticals (LON:HIK)‘s stock had its “hold” rating reaffirmed by equities research analysts at Peel Hunt in a note issued to investors on Thursday.
HIK has been the subject of a number of other research reports. Barclays reiterated an “underweight” rating and set a GBX 1,400 ($18.29) price target on shares of Hikma Pharmaceuticals in a research report on Friday, August 24th. Numis Securities reiterated a “hold” rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, August 15th. Jefferies Financial Group upgraded Hikma Pharmaceuticals to a “buy” rating and lifted their price target for the company from GBX 1,643 ($21.47) to GBX 2,000 ($26.13) in a research report on Tuesday, November 27th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 1,050 ($13.72) price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, August 21st. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of GBX 1,815.71 ($23.73).
Shares of HIK opened at GBX 1,704.50 ($22.27) on Thursday. Hikma Pharmaceuticals has a 12-month low of GBX 814.20 ($10.64) and a 12-month high of GBX 2,346 ($30.65).
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Recommended Story: Can systematic risk be avoided?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.